Simlandi (AVT02) is the second high-concentration, citrate-free adalimumab (Humira) biosimilar to be approved in the Canada market.
Alvotech of Reykjavik, Iceland, has become the second biosimilar developer to announce an approval in the Canadian market for a high-concentration, citrate-free adalimumab biosimilar (100 mg/mL). The product, Simlandi (AVT02), may launch immediately as Canadian health authorities have ruled that clearance should not be impeded by litigation between Alvotech and the innovator company, AbbVie, maker of the reference brand Humira.
Adalimumab is an anti-inflammatory drug used for multiple conditions, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn disease. In Canada, Humira, the reference product, had sales of over $700 million in 2020, according to IQVIA.
In a statement, Alvotech said that “the 40-mg/0.4-mL and 80-mg/0.8-mL presentations of Simlandi, are not subject to the statutory stay, clearing the way for the launch in the Canadian market.”
In the United States, the market for high-concentration adalimumab now represents at least 80% of the market for adalimumab, according to IQVIA, and only Humira is available there; but in Canada, there has been a history of patients not being able to obtain the high-concentration version, which is prized because of its convenience (low-volume administration) and its citrate-free formulation, which reduces the pain experienced by patients.
In Canada recently, Celltrion Healthcare also has won approval for marketing its high-concentration, citrate-free adalimumab biosimilar (Yuflyma; CT-P17).
Both Celltrion and Alvotech have obtained European Commission approval to market Yuflyma and Simlandi, respectively, in the European Union, where the market for high-concentration adalimumab represents about a 60% share of the adalimumab market, according to Celltrion. However, Celltrion has initiated launch in the European Union and Alvotech has yet to announce a launch date. The reasons for the delay have not been disclosed.
In the United States, Alvotech is entangled in litigation with AbbVie over AVT02, and it’s unclear whether this product will reach market in 2022 or beyond. Both Celltrion and Alvotech are awaiting regulatory approval to launch in the United States.
For Alvotech, the Canada Simlandi launch will be managed by JAMP Pharma Group, a Canadian company based in Montreal. Authorization was granted by Health Canada.
“We are extremely proud to be the first Canadian company to offer this value-added option at a considerably lower cost than Humira, Louis Pilon, CEO of JAMP, said in a statement.
Canada has attempted to jump whole hog into biosimilars by introducing mandatory switching policies province by province and most recently in the Northwest Territories. Biosimilars are as safe and efficacious as reference products, and they hold the potential for enormous savings, as their competition forces reference drug producers to lower prices of their brand products.
Globally, Humira is the top-selling drug, netting roughly $20 billion in sales in 2020. The high cost of Humira, an estimated $77,000 per year per patient in the United States, is seen as a significant barrier to access that in some cases forces patients to make hard choices between seeking treatment with this drug and paying for other essentials.
JAMP and Alvotech said their high-concentration formulations will offer patients some flexibility in treatment: “We will also offer a unique 80-mg/0.8-mL dose to Canadian patients that will reduce the number of starting injections by 50% for the patients that require it,” said Bruno Mäder, president and chief operating officer of JAMP.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.